Compare
Biogen vs Gilead Sciences (BIIB vs GILD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Biogen (BIIB) returned +61.9% and Gilead Sciences (GILD) +36.1%; so far this year the figures are +41.1% and +36.0%.
Gilead Sciences is the larger company by market value, about 5.6 times the size of Biogen.
Revenue grew +2.3% at BIIB and +6.5% at GILD over the last year.
BIIB pays no dividend. GILD yields 1.95%.
Data as of the latest close. Not investment advice.
Relative performance
| BIIB | GILD | |
|---|---|---|
| Price | $248.35 | $166.89 |
| 1-day | +1.81% | -0.41% |
| YTD | +41.12% | +35.97% |
| 1 year | +61.87% | +36.15% |
| 3 years | +3.64% | +108.12% |
| Market cap | $36.7B | $207.0B |
| P/E | 107.0 | — |
| P/S | 3.57 | 6.68 |
| P/B | 1.94 | 15.87 |
| Revenue growth | +2.30% | +6.50% |
| EPS growth | -78.90% | -149.00% |
| Gross margin % | 74.0 | 79.9 |
| Net margin % | 3.4 | -12.5 |
| ROE % | 1.8 | -29.6 |
| Debt / equity | 0.39 | 2.01 |
| FCF yield % | 5.6 | 6.7 |
| Dividend yield % | — | 1.95 |
| Beta | 0.33 | 0.37 |
| RSI (14) | 57.0 | 60.2 |
| Technical rating |